/Investor DB

Flagship Pioneering — 2021 Investments

8 investments dated 2021 · listed companies and verified rows first · show all

Generate Biomedicinesgeneratebiomedicines.comin𝕏NASDAQ: GENBSeries B · Nov 2021 · $370M✓ verified

Generate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering.

AI & Machine LearningBiotechDeep TechSomerville, US

Gevorg Grigoryan(Founder)inMichael Nally(Chief Executive Officer)inAvak Kahvejian(Founder)Geoffrey von Maltzahn(Founder)Molly Gibson(Founder)

Co-investorsAlumni VenturesARCH Venture PartnersMarch Capital PartnersNVIDIAAlaska Permanent Fund CorporationALTITUDE LIFE SCIENCE VENTURES+4 more

AllTrnaalltrna.comin𝕏Nov 2021 · $50M✓ verified

Alltrna develops engineered, chemically modified tRNA oligonucleotides as programmable medicines, using proprietary machine learning tools to design tRNA molecules with desired pharmacologic properties.

AI & Machine LearningBiotechDeep TechHealthtech

Lovisa Afzelius(Executive Chair & Founding CEO)inMichelle Werner(CEO)inJoanne Protano(President & Chief Financial Officer)inDave Hava(Chief Scientific Officer)inNerissa Kreher(Chief Medical Officer)inCaroline Köhrer(SVP, Discovery Platform)in

Cellaritycellarity.comin𝕏Series B · Feb 2021 · $120M

Cellarity develops medicines using artificial intelligence and single-cell biology to address disease at the cellular level rather than targeting individual disease markers.

AI & Machine LearningBiotechDeep TechMedical Devices

Avak Kahvejian Nick Plugis(Founder)

Co-investorsAhren Innovation CapitalManta Ray VenturesBlackRock

Ring Therapeuticsringtx.comSeries B · Jul 2021 · $120M

Ring Therapeutics develops vector-based targeted medicines using its Vectorology platform, which engineers conjugates derived from human commensal viruses to deliver diverse therapeutic payloads to specific tissues and cells.

BiotechDeep Tech

Chris McNulty(CEO)

Seventh Senseseventhsense.aiinSep 2021 · $21M

Seventh Sense develops face-based biometric authentication solutions that verify identity without storing facial data, serving organizations and individuals needing secure access control, document signing, and identity verification.

AI & Machine LearningCybersecurityDeep TechDigital HealthSingapore, SG

Ashish KushwahaSam TsuiVarun Chatterji

Co-investors500 Global500 Startups VietnamFlagship VenturesNewpath Partners

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

CIBOLarondeSeventh Sense Biosystems

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.